Chemotherapy Clinical Trial
Official title:
Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial
Recurrent or advanced cervical neuroendocrine carcinoma (NEC) is refractory to multimodal treatment, even to extensive therapy. Chemotherapy, consisting of platinum and etoposide, remains the main therapy for recurrent or advanced cervical NEC. In addition, bevacizumab has shown progression-free benefits in recurrent or advanced cervical cancer. Case report suggested anti-PD-1 antibody may have antitumor activities in NEC. Based on these evidences, a phase 2, single arm trial is conducted to explore the objective response rate (ORR) of platinum/etoposide/bevacizumab/anti-PD-1 antibody (camrelizumab) for the treatment of recurrent or advanced cervical NEC. This trial is to enroll 20 patients, who would accept 6 courses of platinum/etoposide/bevacizumab/camrelizumab. If the patient achieved complete or partial remission, a total period of 12 months bevacizumab/camrelizumab will be given as maintain therapy. The primary endpoint is ORR. The second endpoints are severe adverse events according to criteria of Common Terminology Criteria for Adverse Events (CTCAE) and iRECIST Guideline, and critical changes of laboratory testing.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03652727 -
FX vs. ECG Guidance for PICC Insertion
|
N/A | |
| Not yet recruiting |
NCT05856656 -
Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
| Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
| Recruiting |
NCT00797238 -
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
|
N/A | |
| Not yet recruiting |
NCT05927857 -
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Completed |
NCT04466332 -
Comparison of Two ECG Guided PICC Insertion Techniques
|
N/A | |
| Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
| Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
| Recruiting |
NCT06208436 -
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
|
||
| Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
| Active, not recruiting |
NCT02304640 -
Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
|
||
| Completed |
NCT02298972 -
Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
|
N/A | |
| Terminated |
NCT01249001 -
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
|
Phase 2 | |
| Recruiting |
NCT03089892 -
A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
|
N/A | |
| Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04472403 -
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
|
||
| Terminated |
NCT02982694 -
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
|
Phase 2 |